https://www.ophthalmologytimes.com/view/more-companies-share-upcoming-aao-presentation-information 2024-11-07 0.50 https://www.ophthalmologytimes.com/view/aao-2024-one-simple-change-to-boost-sustainability-in-eye-clinics-stop-discarding-eye-drops-before-they-expire 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/aao-2024-cardiac-arrhythmias-are-associated-with-amd 2024-10-16 0.50 https://www.ophthalmologytimes.com/view/aao-2024-centricity-vision-to-unveil-new-zeptolink-enhancements-for-improved-efficiency-and-control 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/oculis-to-present-phase-3-diamond-program-updates-at-innovate-retina-and-eyecelerator-2024 2024-10-15 0.50 https://www.ophthalmologytimes.com/view/aeye-health-to-attend-aao-annual-meeting-with-diabetic-retinopathy-screening-techonology 2024-10-11 0.50 https://www.ophthalmologytimes.com/view/rising-diabetic-retinopathy-rates-in-youth-signal-potential-public-health-crisis 2024-10-14 0.50 https://www.ophthalmologytimes.com/view/nanoscope-therapeutics-inc-acquires-a-license-for-the-catch-technology 2024-10-10 0.50 https://www.ophthalmologytimes.com/view/pulsesight-therapeutics-sas-to-present-data-on-pst-611-for-dry-amd-ga 2024-10-10 0.50 https://www.ophthalmologytimes.com/view/unity-biotechnology-to-host-in-person-and-virtual-ophthalmology-day 2024-10-09 0.50 https://www.ophthalmologytimes.com/view/applied-science-expands-its-adaptivmd-chronic-care-workflow-technology 2024-10-10 0.50 https://www.ophthalmologytimes.com/view/key-lectures-and-awards-at-the-aao-2024-meeting 2024-10-09 0.50 https://www.ophthalmologytimes.com/view/verana-health-debuts-qdata-explorer-in-advance-of-american-academy-of-ophthalmology-2024-annual-meeting 2024-10-09 0.50 https://www.ophthalmologytimes.com/view/nanoscope-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa 2024-10-10 0.50 https://www.ophthalmologytimes.com/view/modern-retina-parent-company-mjh-life-sciences-acquires-eye-care-conference-envision-summit 2024-10-10 0.50 https://www.ophthalmologytimes.com/view/aao-2024-to-elevate-in-windy-city 2025-02-11 0.50 https://www.ophthalmologytimes.com/view/remidio-receives-cdsco-approval-in-india-for-medios-dr-ai 2024-10-09 0.50 https://www.ophthalmologytimes.com/view/aao-2024-meeting-information-not-to-miss 2024-10-09 0.50 https://www.ophthalmologytimes.com/view/doheny-eye-institute-ophthalmologists-to-present-at-the-aao-2024-annual-meeting 2024-10-09 0.50 https://www.ophthalmologytimes.com/view/belite-bio-doses-the-first-patient-at-the-tokyo-medical-center-in-the-phase-2-3-dragon-ii-clinical-trial 2024-10-09 0.50 https://www.ophthalmologytimes.com/view/national-eye-institute-nei-awards-1-5-million-grant-to-the-medical-college-of-georgia-at-augusta-university-to-study-a-new-treatment-target-for-diabetic-retinopathy- 2024-10-09 0.50 https://www.ophthalmologytimes.com/view/clearside-biomedical-releases-positive-topline-results-from-odyssey-phase-2b-trial-of-suprachoroidal-axitinib-injectable-suspension-in-wet-amd 2024-10-09 0.50 https://www.ophthalmologytimes.com/view/everads-therapy-presented-on-first-in-human-study-of-the-everads-injector-for-suprachoroidal-administration-at-euretina-2024 2024-10-09 0.50 https://www.ophthalmologytimes.com/view/discovery-of-a-common-mechanistic-defect-and-potential-therapies-for-amd-and-related-macular-dystrophies 2024-10-07 0.50 https://www.ophthalmologytimes.com/view/asu-researchers-tap-ai-to-help-people-see-more-clearly 2024-10-07 0.50 https://www.ophthalmologytimes.com/view/small-hyperreflective-retinal-foci-an-in-vivo-imaging-feature-of-resident-microglia-activation-in-geographic-atrophy 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/new-ai-model-reaches-clinical-expert-level-accuracy-in-complex-medical-scans 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/harrow-relaunches-triamcinolone-acetonide-injectable-suspension 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/nyu-langone-receives-1-6-million-grant-from-nih-to-study-alzheimer-parkinson-progression 2024-10-03 0.50 https://www.ophthalmologytimes.com/view/study-finds-caffeine-boosts-inner-retinal-activity-in-young-adults 2024-10-02 0.50 https://www.ophthalmologytimes.com/view/mediwhale-receives-12-million-in-funding-for-ai-retina-scan-technology-that-predicts-cardiovascular-and-metabolic-diseases 2024-10-02 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-crispr-cas-mediated-base-editing-approaches-for-crb1-related-retinal-dystrophy 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/researchers-discover-gene-responsible-for-rare-inherited-eye-disease 2024-09-30 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-ali-erginay-md-red-blue-green-rgb-imaging-modalities 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/early-stage-macular-vascular-and-photoreceptor-changes-in-dme 2024-09-30 0.50 https://www.ophthalmologytimes.com/view/icymi-4-key-interviews-from-our-2024-conference-coverage 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/digital-exclusive-an-interview-with-david-eichenbaum-md-on-his-asrs-2024-presentation 2024-09-30 0.50 https://www.ophthalmologytimes.com/view/digital-exclusive-a-look-at-the-phase-1-helios-trial-with-dilsher-dhoot-md 2024-10-01 0.50 https://www.ophthalmologytimes.com/view/true-to-life-retinal-imaging-with-the-new-ultra-widefield-color-rgb-modality 2024-09-30 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-an-overview-of-the-sing-imt-implant-with-alfonso-savastano-md-phd 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-bahram-bodaghi-md-phd-febo-says-the-congress-starts-with-innovation- 2024-09-25 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-the-cooperative-work-of-an-international-team 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/brain-to-eye--amyloid-transport-a-major-contributor-to-alzheimer-disease-retinopathy 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-the-future-of-medical-retina-is-brilliant-for-clinicians-and-patients 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-ultra-widefield-oct-and-the-benefits-of-improved-imaging 2024-09-27 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-martin-s-zinkernagel-md-phd-on-the-future-of-real-world-ai-use 2024-09-25 0.50 https://www.ophthalmologytimes.com/view/first-patients-enrolled-in-the-clarity-phase-3-study 2024-09-26 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-new-therapeutics-for-wet-amd-address-the-broader-vegf-family 2024-09-27 0.50 https://www.ophthalmologytimes.com/view/zack-dvey-aharon-co-founder-and-ceo-of-aeye-health-named-to-time100-ai-list 2024-09-27 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-genotype-phenotype-correlations-in-a-cohort-of-patients-with-genetically-determined-retinitis-pigmentosa 2024-09-25 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-alexandra-miere-md-phd-sees-oculomics-rising-to-the-top 2024-09-25 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-the-importance-of-the-international-retina-community 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-the-global-voyager-study-provides-real-world-scalable-findings 2024-09-26 0.50 https://www.ophthalmologytimes.com/view/inflammasome-therapeutics-completes-enrollment-of-phase-i-pk-safety-for-k9 2024-09-26 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-kyoko-ohno-matsui-md-phd-shares-a-keynote-on-cutting-edge-technologies-for-pathologic-myopia 2024-09-25 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-boris-stanzel-md-shares-research-on-fluid-monitoring-and-fixation-clouds 2024-09-25 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-magnification-implant-for-ga 2024-09-25 0.50 https://www.ophthalmologytimes.com/view/white-coat-syndrome-and-retinal-vein-occlusion 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/enrollment-complete-of-phase-2b-of-siglec-study-to-assess-safety-and-efficacy-of-avd-104-for-ga-secondary-to-amd 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/early-onset-sepsis-may-be-a-risk-factor-for-rop 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/a-great-leap-forward-in-ophthalmic-drug-delivery- 2024-09-13 0.50 https://www.ophthalmologytimes.com/view/study-socioeconomic-inequality-linked-to-increased-risk-of-amd 2024-09-21 0.50 https://www.ophthalmologytimes.com/view/university-of-arkansas-for-medical-sciences-receives-2-2-million-grant-to-study-efferocytosis-in-retinopathy 2024-09-21 0.50 https://www.ophthalmologytimes.com/view/the-sights-of-stockholm 2024-09-13 0.50 https://www.ophthalmologytimes.com/view/higher-molar-dose-in-the-real-world-and-clinical-trials 2024-09-16 0.50 https://www.ophthalmologytimes.com/view/stealth-biotherapeutics-presents-preclinical-data-on-bevemipretide-s-retinal-delivery-in-amd-models 2024-09-21 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-the-vit-buckle-society-makes-its-euretina-debut 2024-09-23 0.50 https://www.ophthalmologytimes.com/view/faster-identification-of-infants-at-high-risk-of-rop-by-evaluating-the-effects-of-maternal-and-fetal-vascular-malperfusion 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/iris-freckles-potential-biomarker-for-amd 2024-09-20 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-factors-predictive-of-macular-edema-development-in-patients-with-silicone-oil-tamponade 2024-09-17 0.50 https://www.ophthalmologytimes.com/view/ema-announces-positive-opinion-for-sb15-opuviz-samsung-bioepis-and-biogen- 2024-11-15 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-yousif-subhi-md-phd-shares-the-things-that-matter-in-amd-and-central-serous-chorioretinopathy 2024-09-23 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-andrea-govetto-md-phd-says-it-takes-teamwork-to-understand-macular-edema 2024-09-21 0.50 https://www.ophthalmologytimes.com/view/spotlight-on-ga-promoting-early-detection-and-treatment 2024-09-26 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-phase-1-helios-trial-for-otx-tki 2024-09-21 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-unraveling-the-genetic-spectrum-of-combined-retinal-dystrophy-and-hearing-impairment 2024-09-17 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-ricardo-leita-o-guerra-md-msc-fico-speaks-about-multimodal-imaging 2024-09-19 0.50 https://www.ophthalmologytimes.com/view/the-unique-role-of-the-retina-optometrist 2024-09-16 0.50 https://www.ophthalmologytimes.com/view/subretinal-gene-therapy-improves-function-and-structure-in-patients-with-bothnia-dystrophy 2024-09-17 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-ocular-involvement-among-patients-with-covid-19-infection-or-vaccination 2024-09-17 0.50 https://www.ophthalmologytimes.com/view/opthea-completes-process-performance-qualification-ppq- 2024-09-19 0.50 https://www.ophthalmologytimes.com/view/alkeus-pharmaceuticals-shares-results-of-saga-study-of-oral-gildeuretinol-acetate-for-ga 2024-09-19 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-cardio-ocular-syndrome-and-retinal-microvasculature-changes-in-acute-heart-failure 2024-09-17 0.50 https://www.ophthalmologytimes.com/view/euretina-2024-efficacy-results-and-patient-preference-findings-from-the-pagoda-trial 2024-09-17 0.50 https://www.ophthalmologytimes.com/view/4dmt-shares-data-from-phase-1-2-prism-clinical-trial-4front-phase-3-study-design 2024-09-18 0.50 https://www.ophthalmologytimes.com/view/opthea-makes-changes-to-leadership-and-hires-senior-roles 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/oct-based-ai-analysis-brings-changes-in-ga-and-therapeutic-responses-into-sharp-focus 2024-09-13 0.50 https://www.ophthalmologytimes.com/view/atsena-therapeutics-receives-orphan-drug-designation-from-fda-for-atsn-201-gene-therapy-to-treat-x-linked-retinoschisis 2024-09-17 0.50 https://www.ophthalmologytimes.com/view/ani-pharmaceuticals-completes-acquisition-of-alimera-sciences 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/the-current-state-of-gene-therapy-in-managing-neovascular-macular-degeneration 2024-09-17 0.50 https://www.ophthalmologytimes.com/view/the-future-of-retina-care 2024-09-17 0.50 https://www.ophthalmologytimes.com/view/social-factors-associated-with-diabetic-retinopathy-visit-adherence 2024-09-16 0.50 https://www.ophthalmologytimes.com/view/the-world-s-first-whole-eye-and-partial-face-transplant-recipient-continues-recovery-with-viable-eye-1-year-after-landmark-surgery 2024-09-13 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-unveils-children-s-vision-health-map-corresponding-report 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-100x-improvement-in-sight-detected-after-gene-therapy-trial 2024-09-12 0.50 https://www.ophthalmologytimes.com/view/university-of-colorado-ophthalmology-researcher-awarded-funding-to-advance-study-of-uveitis-and-ocular-inflammation 2024-09-12 0.50 https://www.ophthalmologytimes.com/view/industry-preview-ophthalmic-companies-bring-updates-new-research-findings-to-euretina 2024-09-11 0.50 https://www.ophthalmologytimes.com/view/24th-euretina-congress-the-art-of-retina-on-stage-in-barcelona 2024-09-11 0.50 https://www.ophthalmologytimes.com/view/the-implications-of-real-world-data-integration-in-health-care-and-ophthalmology 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/trinity-team-s-gene-therapy-offers-promise-for-treating-glaucoma-as-well-as-amd 2024-09-10 0.50 https://www.ophthalmologytimes.com/view/celebrate-world-retina-day-at-the-2024-euretina-congress 2024-09-11 0.50 https://www.ophthalmologytimes.com/view/lindus-health-announces-all-in-one-ophthalmology-cro- 2024-09-10 0.50 https://www.ophthalmologytimes.com/view/formosa-pharmaceuticals-makes-first-shipment-of-app13007-to-us-for-commercialization 2024-09-10 0.50 https://www.ophthalmologytimes.com/view/boehringer-ingelheim-to-advance-potential-new-treatment-for-ga-following-phase-1-results 2024-09-10 0.50 https://www.ophthalmologytimes.com/view/merck-and-eyebio-announce-initiation-of-phase-2b-3-brunello-trial-evaluating-mk-3000-for-dme 2024-09-05 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-kicks-off-world-sight-day-activities-with-congressional-briefing-on-capitol-hill-partnerships-and-vision-screening-events-nationwide 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/skyline-therapeutics-receives-orphan-drug-designation-from-fda-for-skg1108 2024-09-05 0.50 https://www.ophthalmologytimes.com/view/diagnos-inc-meets-compliance-requirements-for-iso-13485-standard 2024-09-06 0.50 https://www.ophthalmologytimes.com/view/clearside-biomedical-complete-final-participant-visit-in-odyssey-phase-2b-trial 2024-08-30 0.50 https://www.ophthalmologytimes.com/view/foundation-fighting-blindness-to-conduct-a-natural-history-study-of-usher-syndrome-type-3 2024-08-30 0.50 https://www.ophthalmologytimes.com/view/formulation-and-use-patent-issued-to-inmed-for-ocular-delivery-candidate 2024-08-30 0.50 https://www.ophthalmologytimes.com/view/world-sight-day-2024-to-spotlight-pediatric-eye-health 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-shows-ai-may-be-lacking-registry-data 2024-08-28 0.50 https://www.ophthalmologytimes.com/view/research-team-works-to-help-prevent-vision-loss-linked-with-space-travel 2024-08-26 0.50 https://www.ophthalmologytimes.com/view/ocugen-announces-health-canada-approval-to-begin-phase-3-clinical-trial-for-ocu400 2024-08-26 0.50 https://www.ophthalmologytimes.com/view/aiviva-biopharma-completes-enrollment-in-phase-1-clinical-trial-of-aiv007-for-amd-dme 2024-08-26 0.50 https://www.ophthalmologytimes.com/view/conditional-metastasis-free-survival-of-uveal-melanoma-based-on-tumor-size-category 2024-08-22 0.50 https://www.ophthalmologytimes.com/view/wio-2024-an-educator-s-perspective-on-shattering-glass-ceilings-in-ophthalmology 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/wio-2024-integrating-ai-for-postoperative-patient-care 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/wio-2024-get-to-know-the-chairs-of-wio 2024-08-23 0.50 https://www.ophthalmologytimes.com/view/university-of-minnesota-researchers-uncover-possible-pathway-to-prevent-amd 2024-08-22 0.50 https://www.ophthalmologytimes.com/view/wio-2024-skills-labs-and-more 2024-08-22 0.50 https://www.ophthalmologytimes.com/view/wio-2024-a-conversation-with-wio-president-christina-y-weng-md-mba 2024-08-22 0.50 https://www.ophthalmologytimes.com/view/wio-2024-more-than-data 2024-08-22 0.50 https://www.ophthalmologytimes.com/view/visiox-pharmaceuticals-announces-merger-with-ocuvex-therapeutics 2024-08-20 0.50 https://www.ophthalmologytimes.com/view/opus-genetics-receives-pediatric-disease-designation-from-fda-for-opgx-lca5-to-treat-rare-inherited-retinal-disease-lca5 2024-08-20 0.50 https://www.ophthalmologytimes.com/view/eyestem-completes-first-round-of-patient-injections-for-its-dry-amd-treatment 2024-09-10 0.50 https://www.ophthalmologytimes.com/view/akari-therapeutics-receives-positive-and-constructive-pre--investigational-new-drug-for-pas-nomacopan 2024-08-20 0.50 https://www.ophthalmologytimes.com/view/vitamin-d-deficiency-may-be-instrumental-in-retinal-vein-occlusion 2024-08-15 0.50 https://www.ophthalmologytimes.com/view/asrs-releases-public-service-announcement-that-shines-spotlight-on-retina-specialist-care 2024-08-15 0.50 https://www.ophthalmologytimes.com/view/eye-surgery-showcase-goes-to-australian-parliament-house 2024-08-15 0.50 https://www.ophthalmologytimes.com/view/bettis-1-phase-2-trial-enrolls-and-doses-first-patient-with-dme 2024-08-14 0.50 https://www.ophthalmologytimes.com/view/study-finds-medicaid-vision-coverage-for-adults-varies-widely-by-state 2024-08-13 0.50 https://www.ophthalmologytimes.com/view/fda-grants-rare-pediatric-disease-designation-for-atsn-201-for-the-treatment-of-xlrs 2024-08-14 0.50 https://www.ophthalmologytimes.com/view/study-examines-sickle-cell-disease-and-risk-of-large-vessel-retinal-vascular-occlusion 2024-08-13 0.50 https://www.ophthalmologytimes.com/view/university-of-washington-researchers-to-study-the-genetic-causes-of-inherited-retinal-diseases 2024-08-13 0.50 https://www.ophthalmologytimes.com/view/study-reveals-eye-pain-as-leading-cause-of-ophthalmology-and-ed-visits-in-us 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/sandoz-receives-fda-approval-for-aflibercept-abzv-for-the-treatment-of-namd 2024-11-15 0.50 https://www.ophthalmologytimes.com/view/study-shows-economically-disadvantaged-patients-more-likely-to-delay-treatment-for-severe-retinal-detachment 2024-08-09 0.50 https://www.ophthalmologytimes.com/view/lumithera-announces-new-category-iii-cpt-code 2024-08-08 0.50 https://www.ophthalmologytimes.com/view/study-examines-use-of-ai-for-early-detection-of-pediatric-eye-diseases-using-mobile-photos 2024-08-08 0.50 https://www.ophthalmologytimes.com/view/ai-can-aid-with-early-detection-of-diabetic-retinopathy 2024-08-08 0.50 https://www.ophthalmologytimes.com/view/fda-issues-type-c-written-response-for-sol-r-wet-amd-study 2024-08-08 0.50 https://www.ophthalmologytimes.com/view/eyedaptic-unveils-eye6-with-ivy-an-ai-powered-visual-assistant-for-patients-diagnosed-with-age-related-macular-degeneration-and-other-retinal-disorders 2024-08-07 0.50 https://www.ophthalmologytimes.com/view/lupin-s-phase-3-trials-for-ranibizumab-biosimilar-reaches-primary-endpoint 2024-11-15 0.50 https://www.ophthalmologytimes.com/view/fda-notifies-ocugen-to-begin-expanded-access-program-for-rp-patients-for-candidate-ocu400 2024-08-06 0.50 https://www.ophthalmologytimes.com/view/researchers-examine-novel-mechanism-of-retinal-degeneration 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/annexon-provides-update-on-archer-ii-global-registrational-program-in-geographic-atrophy 2024-08-05 0.50 https://www.ophthalmologytimes.com/view/nma-2024-first-in-medicine-an-african-american-perspective-from-1700-to-1940 2024-08-01 0.50 https://www.ophthalmologytimes.com/view/nyc-health-hospitals-harlem-launches-new-surgical-retina-service 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-examines-relationship-between-genotype-phenotype-and-refractive-status-in-patients-of-inherited-retinal-degeneration 2024-08-02 0.50 https://www.ophthalmologytimes.com/view/vision-loss-and-cholesterol-new-factors-associated-with-dementia 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/nma-2024-m-roy-wilson-md-touches-upon-reconceptualizing-the-use-of-race-in-medicine 2024-08-01 0.50 https://www.ophthalmologytimes.com/view/pearls-for-managing-melanocytic-ocular-surface-tumors 2024-08-02 0.50 https://www.ophthalmologytimes.com/view/nma-2024-outgoing-ophthalmology-chair-fasika-woreta-md-sums-up-this-year-in-cornea 2024-08-05 0.50 https://www.ophthalmologytimes.com/view/nma-2024-hot-technologies-in-neuro-ophthalmology 2024-08-02 0.50 https://www.ophthalmologytimes.com/view/adverum-biotechnologies-announces-fda-regenerative-medicine-advanced-therapy-designation-granted-for-ixo-vec-for-treatment-of-wet-amd 2024-08-02 0.50 https://www.ophthalmologytimes.com/view/nih-researchers-discover-potential-therapeutic-target-for-degenerative-eye-disease 2024-08-02 0.50 https://www.ophthalmologytimes.com/view/theriva-biologics-receives-rare-pediatric-drug-designation-from-fda-for-vcn-01-for-the-treatment-of-retinoblastoma 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-real-world-treatment-outcomes-from-a-study-of-patients-with-retinal-vein-occlusion 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/european-medicines-agency-issues-orphan-medicinal-product-designation-for-kio-310-from-kiora-pharmaceuticals 2024-07-30 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-declaring-august-as-children-s-eye-health-and-safety-month 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ocular-therapeutix-enrolls-first-patient-in-phase-3-sol-r-clinical-trial-for-wet-amd 2024-07-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-intraoperative-fluorescein-angiography-improving-outcomes-in-diabetic-vitrectomy 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-ixo-vec-phase-2-luna-study-interim-data-presentation 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/clearside-biomedical-partner-artic-vision-reported-reports-positive-topline-results-from-phase-3-arcatus-trial 2024-07-30 0.50 https://www.ophthalmologytimes.com/view/potential-risk-factors-for-severe-spaceflight-associated-neuro-ocular-syndrome 2024-07-29 0.50 https://www.ophthalmologytimes.com/view/researchers-target-screening-rates-for-diabetic-retinopathy-among-low-income-minority-patients 2024-07-29 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-novel-approach-to-myopic-traction-maculopathy 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/improving-lens-feathering-during-vitrectomy 2024-07-29 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-long-term-results-of-using-indocyanine-green-to-peel-internal-lining-membrane 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/study-examines-the-impact-of-the-covid-19-pandemic-on-ophthalmology-residency-and-fellowship-training 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-safety-and-durability-of-voretigene-neparvovec-rzyl-for-biallelic-rpe65 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-results-of-the-lightsite-iii-study 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-impact-of-vitrectomy-surgery-on-the-progression-of-amd 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/color-blindness-and-differentiating-between-choroidal-melanoma-and-choroidal-nevus 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-illuminating-subclinical-sickle-cell-activities-using-dynamic-oct-angiography 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-restore-trial-100-week-results 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-neurotech-pharmaceuticals-update-on-the-nt-501-device 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ocugen-completes-dosing-in-subjects-with-ga-secondary-to-damd-in-phase-1-2-armada-clinical-trial-of-ocu410 2024-07-25 0.50 https://www.ophthalmologytimes.com/view/samsara-vision-implants-miniature-telescope-in-patient-in-china 2024-07-25 0.50 https://www.ophthalmologytimes.com/view/therapeutic-in-development-to-take-on-dme 2024-07-24 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-real-world-efficacy-and-safety-of-aflibercept-8-mg-in-neovascular-amd 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/photon-trial-outcomes-impact-on-dme-patient-care-in-clinical-practice 2024-07-25 0.50 https://www.ophthalmologytimes.com/view/ama-plans-to-lobby-for-permanent-telemedicine-reimbursement 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-assessing-retinal-vascular-changes-in-alzheimer-disease-with-radiomics-a-preliminary-study-of-fundus-photography 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/implementing-higher-molar-dose-in-your-clinical-practice 2024-08-07 0.50 https://www.ophthalmologytimes.com/view/neuro-oct-by-spryte-medical-receives-breakthrough-device-designation-from-fda 2024-07-25 0.50 https://www.ophthalmologytimes.com/view/pulsar-study-findings-implications-for-treating-namd-in-clinical-practice 2024-07-25 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-the-davio-phase-2-trial-and-upcoming-lugano-phase-3-trial 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-iop-outcomes-with-aflibercept-8-mg-and-2-mg-in-patients-with-dme-through-week-48-of-the-phase-2-3-photon-trial 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/ophthalmology-researchers-develop-framework-to-reduce-spin-in-scientific-reporting 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-durability-of-combination-therapy-of-sozinibercept-in-namd-and-dme 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/study-supplements-slow-disease-progression-during-late-stage-of-dry-amd 2024-07-19 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-socioeconomic-characteristics-associated-with-presenting-visual-acuity-and-foveal-status-in-rhegmatogenous-retinal-detachment 2024-07-29 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-the-calm-study-real-world-outcomes-of-fluocinolone-acetonide-0-18-mg 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-tease-3-study-data-shows-progression-stalled-in-early-stage-stargardt-disease-patients-treated-with-gildeuretinol 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-new-data-for-susvimo-demonstrates-sustained-efficacy-in-dme-dr 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-hk1-associated-retinitis-pigmentosa 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-diabetic-retinopathy-lesion-types-and-distribution-on-ultra-widefield-imaging 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-the-effect-of-suprachoroidal-triamcinolone-acetonide-in-non-infectious-uveitis 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/4d-molecular-therapeutics-announces-positive-initial-interim-24-week-landmark-data-from-population-extension-cohort-of-prism-phase-2-clinical-trial-of-4d-150 2024-07-19 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-fas-inhibition-with-onl-1204-for-ga 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/heidelberg-engineering-announces-fda-clearance-for-its-of-its-octa-module 2024-07-19 0.50 https://www.ophthalmologytimes.com/view/a-case-of-a-79-year-old-pseudophakic-patient-with-amd-and-rapidly-progressing-ga 2024-07-19 0.50 https://www.ophthalmologytimes.com/view/a-case-of-a-79-year-old-female-with-cataracts-and-ga 2024-07-19 0.50 https://www.ophthalmologytimes.com/view/a-case-of-a-70-year-old-female-with-fovea-threatening-ga 2024-07-19 0.50 https://www.ophthalmologytimes.com/view/complement-based-therapies-for-geographic-atrophy-ga- 2024-07-19 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-external-exposures-affect-retina-surgeons-dexterity 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-first-readout-of-the-phase-3-pagoda-trial 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-results-from-part-1-of-the-phase-2-3-siglec-trial-assessing-avd-104-for-ga 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-faretina-dme-study 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-72-week-results-from-the-phase-3-balaton-and-comino-trials 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-sustainability-in-ophthalmology 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-predictive-role-of-outer-retinal-tubulation-in-ga-lesion-growth 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-adverum-biotechnologies-shares-findings-on-ixo-vec-for-wet-amd-from-luna-phase-2-trial 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/aflibercept-subgroup-performance-in-the-phase-2-3-photon-trial-through-week-48 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-what-are-attendees-looking-forward-to-at-the-conference 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/asrs-2024-differential-artery-vein-analysis-improves-octa-performance-for-ai-classification-of-dr 2024-10-04 0.50 https://www.ophthalmologytimes.com/view/study-suggests-jak-inhibitors-may-reduce-amd-risk-in-autoimmune-disease-patients 2024-07-16 0.50 https://www.ophthalmologytimes.com/view/merck-completes-acquisition-of-eyebio 2024-07-16 0.50 https://www.ophthalmologytimes.com/view/bascom-palmer-eye-institute-ranked-as-number-1-hospital-in-ophthalmology 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-details-early-detection-of-vision-loss-in-amd 2024-07-16 0.50 https://www.ophthalmologytimes.com/view/case-western-reserve-university-receives-1-5-million-grant-from-foundation-fighting-blindness-to-test-possible-new-treatment-for-inherited-retinal-disease 2024-07-12 0.50 https://www.ophthalmologytimes.com/view/beacon-therapeutics-to-assess-abeona-s-aav204-capsid-for-potential-gene-therapies 2024-07-12 0.50 https://www.ophthalmologytimes.com/view/docgo-inc-and-spect-teaming-up-to-bring-vision-screening-to-the-people 2024-07-11 0.50 https://www.ophthalmologytimes.com/view/impact-report-highlights-outcomes-of-moorfields-eye-charity-programs 2024-07-12 0.50 https://www.ophthalmologytimes.com/view/more-companies-announce-asrs-2024-presentations 2024-09-23 0.50 https://www.ophthalmologytimes.com/view/approach-to-wet-amd-treatment-explores-vegf-c-and-vegf-d-pathways 2024-07-11 0.50 https://www.ophthalmologytimes.com/view/marjan-farid-md-recognized-for-eye-care-innovations 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-zeroes-in-on-new-target-for-treatment-of-one-type-of-macular-degeneration 2024-07-08 0.50 https://www.ophthalmologytimes.com/view/genentech-receives-fda-approval-to-relaunch-susvimo 2024-07-09 0.50 https://www.ophthalmologytimes.com/view/study-suggests-potential-link-between-semaglutide-and-risk-of-non-arteritic-ischemic-optic-neuropathy 2024-07-08 0.50 https://www.ophthalmologytimes.com/view/beacon-therapeutics-secures-170-million-in-series-b-funding 2024-07-08 0.50 https://www.ophthalmologytimes.com/view/phase-1-trial-of-pmc-403-introduces-multi-dose-cohort 2024-07-02 0.50 https://www.ophthalmologytimes.com/view/asrs-premier-meeting-for-retina-science-and-innovation 2024-06-27 0.50 https://www.ophthalmologytimes.com/view/fda-approves-faricimab-svoa-prefilled-syringe 2024-07-05 0.50 https://www.ophthalmologytimes.com/view/alcon-completes-acquisition-of-belkin-vision 2024-07-02 0.50 https://www.ophthalmologytimes.com/view/european-union-s-committee-for-medicinal-products-for-human-use-issues-negative-opinion-on-apellis-pegcetacoplan-syfovre-injection 2024-07-02 0.50 https://www.ophthalmologytimes.com/view/ema-issues-positive-chmp-opinion-for-faricimab-in-third-indication-rvo 2024-07-02 0.50 https://www.ophthalmologytimes.com/view/altos-biologics-submits-marketing-authorization-application-to-the-ema-for-alt-l9-an-aflibercept-biosimilar 2024-11-15 0.50 https://www.ophthalmologytimes.com/view/low-risk-of-elevated-iop-with-lampalizumab-for-geographic-atrophy-over-1-year 2024-07-02 0.50 https://www.ophthalmologytimes.com/view/fda-approves-formycon-s-biosimilar-to-eylea-aflibercept-mrbb-ahzantive- 2024-11-15 0.50 https://www.ophthalmologytimes.com/view/geographic-atrophy-and-future-plans-what-residents-should-consider 2024-07-02 0.50 https://www.ophthalmologytimes.com/view/amd-and-irds-what-residents-should-know 2024-07-01 0.50 https://www.ophthalmologytimes.com/view/the-big-picture-5-ways-retinal-imaging-is-progressing 2024-07-31 0.50 https://www.ophthalmologytimes.com/view/companies-begin-to-announce-data-presentations-for-asrs-2024 2024-06-26 0.50 https://www.ophthalmologytimes.com/view/yosemite-rhine-post-hoc-analyses-faricimab-achieved-similar-visual-and-anatomic-results-to-aflibercept-in-patients-with-20-50-or-worse-vision 2024-06-27 0.50 https://www.ophthalmologytimes.com/view/4dmt-receives-ind-clearance-for-4d-175-for-treatment-of-geographic-atrophy 2024-06-27 0.50 https://www.ophthalmologytimes.com/view/euretina-introduces-ramin-tadayoni-award-in-honor-of-late-president 2024-06-27 0.50 https://www.ophthalmologytimes.com/view/retinai-discovery-from-ikerian-receives-class-iia-mdr-registration-in-eu 2024-06-25 0.50 https://www.ophthalmologytimes.com/view/study-finds-gene-variant-may-underlie-diabetes-disparities 2024-06-25 0.50 https://www.ophthalmologytimes.com/view/change-for-the-better-where-the-future-of-surgery-may-be-going 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ani-pharmaceuticals-to-expand-footprint-into-ophthalmology-with-acquisition-of-alimera-sciences 2024-06-24 0.50 https://www.ophthalmologytimes.com/view/a-look-at-arvo-2024 2024-06-17 0.50 https://www.ophthalmologytimes.com/view/study-common-cholesterol-lowering-drug-found-to-slow-vision-loss-in-patients-diagnosed-with-diabetes 2024-06-25 0.50 https://www.ophthalmologytimes.com/view/ocugen-announces-data-and-safety-monitoring-board-approves-enrollment-in-high-dose-cohort-3-in-gardian-study-for-stargardt-disease 2024-06-24 0.50 https://www.ophthalmologytimes.com/view/repurposed-drug-may-help-stabilize-vision-in-rare-disease 2024-06-24 0.50 https://www.ophthalmologytimes.com/view/true-to-life-retinal-imaging-with-the-new-ultrawidefield-color-rgb-modality 2024-06-25 0.50 https://www.ophthalmologytimes.com/view/latest-tech-trends-to-benefit-patients-with-amd 2024-06-17 0.50 https://www.ophthalmologytimes.com/view/ocugen-doses-first-patient-in-phase-3-limelight-clinical-trial-for-ocu400 2024-06-20 0.50 https://www.ophthalmologytimes.com/view/treatment-options-for-patients-with-geographic-atrophy 2024-06-17 0.50 https://www.ophthalmologytimes.com/view/harrow-provides-triamcinolone-acetonide-injectable-suspension-relaunch-update 2024-06-20 0.50 https://www.ophthalmologytimes.com/view/neurotech-pharmaceuticals-receives-priority-review-of-bla-for-nt-501-for-treatment-of-mactel 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/enhancing-patient-outcomes 2024-07-08 0.50 https://www.ophthalmologytimes.com/view/cts-2024-results-of-axpaxli-clinical-trials-presented 2024-06-18 0.50 https://www.ophthalmologytimes.com/view/revopsis-kemwell-biopharma-enter-strategic-partnership-to-expedite-development-of-biologics-for-treatment-of-namd 2024-06-18 0.50 https://www.ophthalmologytimes.com/view/satellite-clinics-and-other-strategies-to-enhance-rural-ophthalmology 2024-06-17 0.50 https://www.ophthalmologytimes.com/view/office-vitrectomy-a-full-scale-replacement-for-the-asc-and-hospital 2024-06-17 0.50 https://www.ophthalmologytimes.com/view/overcoming-the-wet-amd-treatment-gap 2024-06-18 0.50 https://www.ophthalmologytimes.com/view/real-world-experience-with-intravitreal-pegcetacoplan-for-the-treatment-of-ga 2024-06-17 0.50 https://www.ophthalmologytimes.com/view/consensus-clinical-trial-design-for-the-treatment-of-intermediate-amd 2024-06-17 0.50 https://www.ophthalmologytimes.com/view/combining-imaging-modalities-could-enable-earlier-identification-of-diabetic-retinopathy 2024-06-13 0.50 https://www.ophthalmologytimes.com/view/pegcetacoplan-injection-preserves-visual-function-at-36-weeks-in-patients-with-geographic-atrophy 2024-06-13 0.50 https://www.ophthalmologytimes.com/view/beacon-therapeutics-treats-first-patient-in-vista-registrational-trial-for-agtc-501 2024-06-13 0.50 https://www.ophthalmologytimes.com/view/sleep-supplement-melatonin-may-be-linked-to-lower-risk-of-amd 2024-06-10 0.50 https://www.ophthalmologytimes.com/view/4dmt-presents-injection-free-subgroup-analyses-from-phase-2-prism-randomized-dose-expansion-cohort-in-wet-amd 2024-06-10 0.50 https://www.ophthalmologytimes.com/view/cts-2024-faricimab-vs-aflibercept-in-the-reduction-of-exudates-in-y-r-trials 2024-06-06 0.50 https://www.ophthalmologytimes.com/view/cts-2024-24-week-results-from-the-prism-trials 2024-06-10 0.50 https://www.ophthalmologytimes.com/view/cts-2024-home-oct-and-amd-monitoring 2024-06-06 0.50 https://www.ophthalmologytimes.com/view/cts-2024-first-time-data-from-the-calm-registry 2024-06-06 0.50 https://www.ophthalmologytimes.com/view/cts-2024-considering-structural-and-functional-biomarkers-in-dry-amd 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/research-highlights-retinal-detachment-risks-in-pediatric-marfan-syndrome-patients-following-lens-removal 2024-06-06 0.50 https://www.ophthalmologytimes.com/view/italian-study-finds-rare-eye-tumor-in-child-suggests-genetic-syndrome-link 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/stealth-biotherapeutics-enrolls-first-patient-in-global-phase-3-clinical-program-for-elamipretide-in-patients-diagnosed-with-dry-amd 2024-06-06 0.50 https://www.ophthalmologytimes.com/view/avirmax-biopharma-inc-receives-ind-approval-from-fda 2024-06-05 0.50 https://www.ophthalmologytimes.com/view/zeiss-announces-oct-technology-enhancements-to-better-support-growing-era-of-data-driven-patient-care 2024-06-04 0.50 https://www.ophthalmologytimes.com/view/opthea-to-present-data-at-clinical-trials-at-the-summit-2024 2024-06-05 0.50 https://www.ophthalmologytimes.com/view/is-artificial-intelligence-ai-the-solution-to-saving-ophthalmologists-time- 2024-06-05 0.50 https://www.ophthalmologytimes.com/view/what-to-expect-from-clinical-trials-at-the-summit-2024 2024-06-04 0.50 https://www.ophthalmologytimes.com/view/study-examines-electromagnetic-driving-system-for-5-dof-manipulation-in-intraocular-microsurgery 2024-06-03 0.50 https://www.ophthalmologytimes.com/view/data-and-safety-monitoring-board-approves-simultaneous-enrollment-in-cohort-3-and-phase-2-initiation-in-ocu410-armada-study-for-ga 2024-06-04 0.50 https://www.ophthalmologytimes.com/view/merck-to-acquire-eyebio-for-upfront-payment-of-1-3-billion 2024-05-31 0.50 https://www.ophthalmologytimes.com/view/verana-health-launches-qdata-uveitic-macular-edema-module 2024-05-31 0.50 https://www.ophthalmologytimes.com/view/ai-big-data-and-personalized-medicine-scientists-reveal-playbook-designed-to-revolutionize-healthcare 2024-05-31 0.50 https://www.ophthalmologytimes.com/view/study-taking-electroretinography-to-the-next-level-with-soft-multi-electrode-system 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/opthea-completes-enrollment-in-pivotal-phase-3-clinical-program-with-sozinibercept-in-wet-amd 2024-05-31 0.50 https://www.ophthalmologytimes.com/view/study-examines-how-neurons-build-a-3d-vascular-structure-to-keep-the-retina-healthy 2024-05-30 0.50 https://www.ophthalmologytimes.com/view/study-low-dose-aspirin-doesn-t-affect-the-incidence-or-progression-of-amd 2024-05-28 0.50 https://www.ophthalmologytimes.com/view/h5n1-bird-flu-second-person-infected-in-us-with-main-symptom-of-conjunctivitis 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/diabetes-drug-suppresses-retinal-angiogenesis-in-mice 2024-05-28 0.50 https://www.ophthalmologytimes.com/view/ocular-metastases-patient-profile-in-a-brazilian-tertiary-hospital 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/us-fda-issues-approval-for-two-aflibercept-biosimilars 2024-11-15 0.50 https://www.ophthalmologytimes.com/view/rwc-2024-an-overview-of-real-world-geographic-atrophy-data 2024-05-23 0.50 https://www.ophthalmologytimes.com/view/rwc-2024-updates-on-the-davio-2-trial-for-eyp-1901 2024-05-21 0.50 https://www.ophthalmologytimes.com/view/pegcetacoplan-may-delay-rpe-and-photoreceptor-damage-in-ga 2024-05-21 0.50 https://www.ophthalmologytimes.com/view/rwc-2024-what-if-diabetic-retinopathy-patients-are-lost-to-follow-up- 2024-05-21 0.50 https://www.ophthalmologytimes.com/view/rwc-2024-surgical-retina-tools-used-in-practice 2024-05-15 0.50 https://www.ophthalmologytimes.com/view/study-high-frequency-electrical-noise-may-result-in-congenital-night-blindness 2024-05-21 0.50 https://www.ophthalmologytimes.com/view/annexon-shows-new-analyses-of-anx007-from-phase-2-archer-trial-on-geographic-atrophy 2024-05-21 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-kicks-off-it-started-with-an-eye-exam- 2024-05-21 0.50 https://www.ophthalmologytimes.com/view/mental-health-and-ophthalmology 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/rwc-2024-anesthesia-for-intravitreal-injections 2024-05-16 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-analysis-of-anterior-chamber-inflammation-through-automated-quantitative-assessment-of-swept-source-anterior-segment-oct-images 2024-05-15 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-reduction-in-hard-exudates-with-faricimab-vs-aflibercept-in-patients-with-dme 2024-05-15 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-exploratory-analysis-of-pivotal-phase-3-trials-yosemite-and-rhine-for-vabysmo-in-dme 2024-05-15 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-abnormal-subendothelial-matrix-exacerbates-choroidal-endothelial-cell-death-in-early-age-related-macular-degeneration 2024-05-15 0.50 https://www.ophthalmologytimes.com/view/rwc-2024-week-52-safety-and-efficacy-data-from-the-us-phase-1-trial-of-otx-tki 2024-05-16 0.50 https://www.ophthalmologytimes.com/view/ocugen-completes-dosing-in-second-cohort-of-gardian-clinical-trial-for-stargardt-disease 2024-05-16 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-feasibility-and-clinical-efficacy-of-an-oct-b-scan-of-interest-tool 2024-05-15 0.50 https://www.ophthalmologytimes.com/view/treating-geographic-atrophy-in-patients-with-concurrent-neovascular-amd 2024-05-15 0.50 https://www.ophthalmologytimes.com/view/managing-a-patient-with-bilateral-geographic-atrophy 2024-05-15 0.50 https://www.ophthalmologytimes.com/view/fda-approved-therapies-for-geographic-atrophy 2024-05-15 0.50 https://www.ophthalmologytimes.com/view/geographic-atrophy-overview-diagnosis-and-progression 2024-05-15 0.50 https://www.ophthalmologytimes.com/view/rwc-2024-bionic-vision-technology---restoration-of-the-functional-vision-of-late-stage-retinitis-pigmentosa-patients 2024-05-15 0.50 https://www.ophthalmologytimes.com/view/study-virus-that-causes-covid-19-can-penetrate-blood-retinal-barrier-and-may-damage-vision 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/kodiak-sciences-treats-first-patients-in-phase-3-glow2-study-of-tarcocimab-tedromer-in-diabetic-retinopathy 2024-05-14 0.50 https://www.ophthalmologytimes.com/view/outlook-therapeutics-submits-uk-marketing-authorization-application-for-wet-amd-treatment 2024-05-14 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-emily-chew-md-talks-about-her-proctor-award-lecture 2024-05-13 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-anand-swaroop-phd-friedenwald-award-lecture-recipient-talks-about-lecture-and-meaning-of-award 2024-05-13 0.50 https://www.ophthalmologytimes.com/view/eyepoint-pharmaceutical-s-phase-2-pavia-falls-short-of-primary-endpoint 2024-05-13 0.50 https://www.ophthalmologytimes.com/view/study-cripsr-gene-editing-leads-to-improvements-in-vision-for-people-with-inherited-blindness 2024-05-13 0.50 https://www.ophthalmologytimes.com/view/recurrent-uveitis-potential-after-covid-19-vaccination-in-patients-with-a-uveitis-history 2024-05-13 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-predicting-3-year-myopia-control-efficacy-from-1-year-data 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/rwc-2024-rationale-for-the-design-of-the-phase-3-superiority-clinical-trials-of-sozinibercept-combination-therapy 2024-05-15 0.50 https://www.ophthalmologytimes.com/view/rwc-2024-new-technologies-for-navigated-peripheral-oct-of-the-vitreoretinal-interface-and-retina 2024-05-11 0.50 https://www.ophthalmologytimes.com/view/rwc-2024-longitudinal-bcva-and-safety-analysis-of-mutation-agnostic-mco-010-optogenetic-therapy-for-retinitis-pigmentosa 2024-05-15 0.50 https://www.ophthalmologytimes.com/view/rwc-2024-gene-therapy-associated-uveitis 2024-05-11 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-daniel-saban-phd-on-the-cogan-lecture-2024 2024-05-07 0.50 https://www.ophthalmologytimes.com/view/rwc-2024-beneficial-effects-on-macular-function-with-continuous-pegcetacoplan-treatment-oaks-derby-and-gale-open-label-extension 2024-05-06 0.50 https://www.ophthalmologytimes.com/view/rwc-2024-strategies-to-minimize-pain-with-intravitreal-injections 2024-05-10 0.50 https://www.ophthalmologytimes.com/view/rwc-2024-4dmt-s-gene-therapy-program-for-wet-amd 2024-05-10 0.50 https://www.ophthalmologytimes.com/view/rwc-2024-an-iris-database-look-at-triamcinolone-acetonide 2024-05-10 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-reliability-of-contact-specular-microscopy-in-the-corneal-endothelium 2024-05-07 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-mapping-the-melanocortin-receptors-in-the-human-eye 2024-05-07 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-genotype-specific-differences-in-mitochondrial-function 2024-05-07 0.50 https://www.ophthalmologytimes.com/view/native-study-fewer-subretinal-aflibercept-injections-needed-for-submacular-hemorrhages-associated-with-namd-compared-with-intravitreal-injections 2024-05-07 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-12-month-results-of-mutation-agnostic-optogenetic-program-for-patients-with-severe-vision-loss-from-retinitis-pigmentosa 2024-05-07 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-impact-of-early-intraretinal-fluid-reduction-on-one-year-outcomes-in-diabetic-macular-edema 2024-05-13 0.50 https://www.ophthalmologytimes.com/view/highlighting-diversity-equity-and-inclusion-at-retina-world-congress 2024-05-08 0.50 https://www.ophthalmologytimes.com/view/companies-to-highlight-data-at-retina-world-congress-2024 2024-09-23 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-post-hoc-analysis-of-phase-3-trial-on-sb15 2024-05-07 0.50 https://www.ophthalmologytimes.com/view/prior-intravitreal-injections-may-be-associated-with-risk-of-postoperative-cataract-surgery-complications 2024-04-30 0.50 https://www.ophthalmologytimes.com/view/three-year-interim-results-of-the-perceive-study 2024-04-30 0.50 https://www.ophthalmologytimes.com/view/research-suggests-tear-fluid-testing-as-promising-method-for-huntington-s-disease-monitoring 2024-04-30 0.50 https://www.ophthalmologytimes.com/view/study-supports-including-tylectomy-in-multimodel-therapy-for-retinoblastoma 2024-04-30 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-post-hoc-analysis-of-gobi-and-mojave-trials-for-perfluorohexyloctane 2024-04-30 0.50 https://www.ophthalmologytimes.com/view/efficacy-and-safety-of-aflibercept-8-mg-in-photon-trial-in-dmo 2024-05-07 0.50 https://www.ophthalmologytimes.com/view/efficacy-and-safety-of-aflibercept-8-mg-in-pulsar-trial-in-neovascular-amd 2024-05-07 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-researchers-drive-innovation-in-retinal-research 2024-05-06 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-functional-microperimetric-correlates-of-oct-structural-features-in-amd 2024-05-06 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-study-validates-chatgpt-4-0-as-potential-uveitis-patient-resource 2024-05-06 0.50 https://www.ophthalmologytimes.com/view/study-reveals-lower-vision-specific-quality-of-life-in-children-with-cortical-cerebral-visual-impairment 2024-04-30 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-baruch-kuppermann-md-phd-discusses-durability-of-a-pan-vegf-tyrosine-kinase-inhibitor 2024-05-06 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-five-year-prospective-study-comparing-ocular-stiffness-parameters-in-patients-with-diabetes-with-and-without-retinopathy 2024-04-30 0.50 https://www.ophthalmologytimes.com/view/visual-recovery-in-open-globe-injuries-with-nlp-vision-cannot-be-predicted-based-on-clinical-features 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-deep-learning-model-for-ga-segmentation-adaptable-to-ss-oct-and-sd-oct-data 2024-05-05 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-what-retinal-specialists-can-learn-about-dril-from-the-point-study 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-protocol-aa-from-the-drcr-retina-network 2024-05-05 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-36-month-data-from-the-gale-study-of-pegcetacoplan 2024-05-05 0.50 https://www.ophthalmologytimes.com/view/study-identifies-risk-factors-associated-with-diabetic-retinopathy-in-youth-with-type-1-diabetes 2024-04-30 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-understanding-the-reading-problem-for-patients-with-central-vision-loss 2024-05-01 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-vision-related-activity-difficulties-in-people-diagnosed-with-namd-and-vision-impairment 2024-05-01 0.50 https://www.ophthalmologytimes.com/view/arvo-2024-extended-treatment-outcomes-and-the-potential-for-q20w-dosing-with-faricimab-in-namd 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/correlation-between-visual-markers-and-neurological-deficits-in-mouse-model-of-ms 2024-04-30 0.50 https://www.ophthalmologytimes.com/view/results-of-daily-low-level-red-light-therapy-suggests-slowed-progression-of-ser-and-al 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-reports-potential-recurrent-uveitis-after-covid-19-vaccination-in-patients-with-a-uveitis-history 2024-05-02 0.50 https://www.ophthalmologytimes.com/view/aeye-health-receives-fda-clearance-for-first-ever-fully-autonomous-ai-for-portable-dr-screening 2024-05-02 0.50 https://www.ophthalmologytimes.com/view/inflammasome-therapeutics-doses-first-patient-in-phase-1-trial-of-kamuvudine-8-for-geographic-atrophy 2024-05-02 0.50 https://www.ophthalmologytimes.com/view/coave-therapeutics-showcases-its-aligater-platform-for-generating-conjugated-aav-vectors-to-deliver-ocular-gene-therapy-through-suprachoroidal-route 2024-04-30 0.50 https://www.ophthalmologytimes.com/view/data-from-self-tonometry-supports-glaucoma-treatment-decisions 2024-05-01 0.50 https://www.ophthalmologytimes.com/view/duke-biomedical-engineering-chairman-and-oct-pioneer-joseph-izatt-passes-away 2024-04-30 0.50 https://www.ophthalmologytimes.com/view/retinal-vein-occlusion-rvo-to-feature-in-presentations-at-upcoming-arvo-2024-conference 2024-04-29 0.50 https://www.ophthalmologytimes.com/view/more-companies-release-information-on-upcoming-presentations-at-arvo-2024 2024-09-23 0.50 https://www.ophthalmologytimes.com/view/unity-biotechnology-extends-phase-2b-aspire-study-of-uxb1325-from-24-weeks-to-36-weeks 2024-04-26 0.50 https://www.ophthalmologytimes.com/view/arvo-flying-high-in-seattle 2024-04-26 0.50 https://www.ophthalmologytimes.com/view/prevent-blindness-declares-may-inherited-retinal-disease-genetic-testing-awareness-month-to-expand-knowledge-on-ird-testing 2024-05-08 0.50 https://www.ophthalmologytimes.com/view/phoenix-micron-inc-and-artikode-intelligence-team-up-to-enhance-oct-imaging-with-ai 2024-04-25 0.50 https://www.ophthalmologytimes.com/view/companies-begin-to-announce-their-plans-for-data-presentations-at-arvo-2024 2024-09-23 0.50 https://www.ophthalmologytimes.com/view/vision-simulator-provides-interactive-tool-highlighting-the-vision-loss-caused-by-retinal-diseases 2024-04-23 0.50 https://www.ophthalmologytimes.com/view/wvu-medicine-to-expand-relocate-wvu-eye-institute 2024-04-23 0.50 https://www.ophthalmologytimes.com/view/retina-community-mourns-sudden-loss-of-ramin-tadayoni-md-phd 2024-04-22 0.50 https://www.ophthalmologytimes.com/view/ocugen-completes-dosing-of-subjects-with-geographic-atrophy-in-cohort-2-of-phase-1-2-armada-clinical-trial-of-ocu410 2024-04-22 0.50 https://www.ophthalmologytimes.com/view/ocular-therapeutix-announces-positive-topline-phase-1-data-for-axpaxli-in-diabetic-retinopathy 2024-04-19 0.50 https://www.ophthalmologytimes.com/view/saliogen-therapeutics-taps-development-candidate-for-abca4-mediated-stargardt-disease 2024-04-19 0.50 https://www.ophthalmologytimes.com/view/rising-cost-of-diabetic-medications-impact-individuals-as-well-as-medicaid-and-medicare 2024-04-18 0.50 https://www.ophthalmologytimes.com/view/orbis-international-continues-virtual-clinical-education-in-partnership-with-heidelberg-engineering 2024-04-18 0.50 https://www.ophthalmologytimes.com/view/selecting-the-right-patients-for-anti-vegf-biosimilar-therapy 2024-04-18 0.50 https://www.ophthalmologytimes.com/view/impact-of-biosimilars-on-the-healthcare-system 2024-04-18 0.50 https://www.ophthalmologytimes.com/view/key-clinical-findings-on-the-efficacy-safety-profile-and-immunogenicity-of-biosimilar-sb11 2024-04-18 0.50 https://www.ophthalmologytimes.com/view/review-of-the-phase-iii-clinical-trial-for-biosimilar-sb11 2024-04-18 0.50 https://www.ophthalmologytimes.com/view/biosimilar-approval-process-by-regulatory-bodies 2024-04-18 0.50 https://www.ophthalmologytimes.com/view/overview-of-biosimilars 2024-04-18 0.50 https://www.ophthalmologytimes.com/view/need-for-awareness-about-biosimilars 2024-04-18 0.50 https://www.ophthalmologytimes.com/view/i-screen-project-set-to-use-ai-for-amd-diagnosis-across-europe 2024-04-16 0.50 https://www.ophthalmologytimes.com/view/a-wireless-visual-prosthesis-stimulates-neurons-to-produce-a-new-form-of-artificial-sight 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/opthea-highlights-latest-phase-3-trials-for-sozinibercept 2024-04-15 0.50 https://www.ophthalmologytimes.com/view/kiora-pharmaceuticals-receives-grant-to-fund-novel-clinical-trial-endpoints-for-inherited-retinal-diseases 2024-04-15 0.50 https://www.ophthalmologytimes.com/view/dnase-i-a-potential-treatment-for-rvo 2024-04-11 0.50 https://www.ophthalmologytimes.com/view/india-based-eyestem-receives-approval-to-commence-human-trial-for-eyecyte-rpe-for-amd 2024-04-11 0.50 https://www.ophthalmologytimes.com/view/toku-appoints-of-professor-michael-v-mcconnell-md-msee-to-chief-health-officer 2024-04-09 0.50 https://www.ophthalmologytimes.com/view/report-ai-makes-retinal-imaging-100-times-faster-than-manual-method 2024-04-11 0.50 https://www.ophthalmologytimes.com/view/kurt-blasena-joins-digital-diagnostics-as-chief-commercial-officer 2024-04-09 0.50 https://www.ophthalmologytimes.com/view/vigeneron-doses-first-patient-in-phase-1b-clinical-trial-of-vg901-for-the-intravitreal-treatment-of-rp 2024-04-10 0.50 https://www.ophthalmologytimes.com/view/eyepoint-shared-additions-to-scientific-advisory-board-and-conditional-approval-of-trade-name-for-eyp-1901 2024-04-09 0.50 https://www.ophthalmologytimes.com/view/john-han-pharmd-named-vice-president-medical-affairs-for-opthea-limited 2024-04-11 0.50 https://www.ophthalmologytimes.com/view/safflower-injected-as-prophylaxis-for-rvo-in-rabbits 2024-04-09 0.50 https://www.ophthalmologytimes.com/view/nfe2l3-a-neuroprotectant-and-possible-therapeutic-target-for-cns-injury-disease 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/data-and-safety-monitoring-board-dsmb-for-ocugen-s-phase-1-2-armada-clinical-approves-medium-dose-of-ocu410 2024-04-09 0.50 https://www.ophthalmologytimes.com/view/ocugen-inc-announces-fda-clearance-of-ind-amendment-to-initiate-ocu400-phase-3-clinical-trial 2024-04-08 0.50 https://www.ophthalmologytimes.com/view/dexamethasone-and-bevacizumab-for-dme-individualized-treatment-advocated 2024-04-04 0.50 https://www.ophthalmologytimes.com/view/less-may-be-more-in-a-real-world-study-of-anti-vegf-therapy-for-dme 2024-04-04 0.50 https://www.ophthalmologytimes.com/view/promoting-treatment-adherence-in-namd-and-dme 2024-04-05 0.50 https://www.ophthalmologytimes.com/view/safety-considerations-for-new-therapies 2024-04-05 0.50 https://www.ophthalmologytimes.com/view/early-real-world-experiences-with-faricimab-and-aflibercept-8mg 2024-04-05 0.50 https://www.ophthalmologytimes.com/view/powers-company-announces-formation-of-philanthropic-program-lion-s-share 2024-04-04 0.50 https://www.ophthalmologytimes.com/view/beyond-the-eclipse-the-long-term-effects-of-solar-retinopathy 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/roivant-announces-positive-neptune-study-results-for-brepocitinib-in-non-infectious-uveitis 2024-04-04 0.50 https://www.ophthalmologytimes.com/view/the-value-of-real-world-insights-in-ophthalmology-and-geographic-atrophy-ga-treatment 2024-04-11 0.50 https://www.ophthalmologytimes.com/view/wayne-state-university-researchers-uncover-potential-treatment-targets-for-zika-virus-related-eye-abnormalities 2024-04-02 0.50 https://www.ophthalmologytimes.com/view/exonate-to-present-full-phase-ib-iia-trial-data-of-exn407-for-treatment-of-dr-dme-at-arvo 2024-04-02 0.50 https://www.ophthalmologytimes.com/view/clinical-trials-companies-tackle-amd-in-early-2024 2024-03-28 0.50 https://www.ophthalmologytimes.com/view/ophthalmology-s-moon-shot-donation-fast-tracking-bascom-palmer-s-whole-eye-transplant-initiative 2024-03-28 0.50 https://www.ophthalmologytimes.com/view/researchers-use-viscous-seaweed-to-treat-retinal-detachment 2024-03-28 0.50 https://www.ophthalmologytimes.com/view/abvc-biopharma-reaches-global-licensing-deal-for-ophthalmology-pipeline 2024-03-28 0.50 https://www.ophthalmologytimes.com/view/understanding-the-risks-4-factors-that-may-contribute-to-amd 2024-03-26 0.50 https://www.ophthalmologytimes.com/view/terry-kim-md-joining-alcon-as-chief-medical-officer-and-head-of-global-medical-safety 2024-03-28 0.50 https://www.ophthalmologytimes.com/view/patient-selection-for-new-namd-and-dme-therapies 2024-03-29 0.50 https://www.ophthalmologytimes.com/view/using-steroids-in-dme-treatment 2024-03-29 0.50 https://www.ophthalmologytimes.com/view/cleveland-clinic-ophthalmologist-nicole-bajic-md-shares-insights-from-the-path-of-totality 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/preparing-for-the-total-solar-eclipse-what-ophthalmologists-should-know 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/retinal-vascular-health-4-insights-ophthalmologists-should-keep-in-mind-for-2024 2024-03-26 0.50 https://www.ophthalmologytimes.com/view/astellas-receives-permanent-j-code-for-avacincaptad-pegol-intravitreal-solution-for-ga 2024-03-28 0.50 https://www.ophthalmologytimes.com/view/belite-bio-completes-submission-to-pmda-to-initiate-dragon-ii-trial-of-tinlarebant-for-the-treatment-of-adolescent-stargardt-disease-in-japan 2024-03-26 0.50 https://www.ophthalmologytimes.com/view/bluerock-therapeutics-and-foundation-fighting-blindness-collaborate-to-add-new-cohort-to-uni-rare-study-evaluating-inherited-retinal-diseases 2024-03-26 0.50 https://www.ophthalmologytimes.com/view/opus-genetics-completes-dosing-of-the-first-cohort-in-phase-1-2-trial-evaluating-the-subretinal-delivery-of-opgx-lca5 2024-03-26 0.50 https://www.ophthalmologytimes.com/view/phase-ib-iia-trial-of-exn407-eye-drops-from-exonate-demonstrates-safety-and-tolerability 2024-03-26 0.50 https://www.ophthalmologytimes.com/view/nanoscope-therapeutics-lead-candidate-mco-010-meets-endpoints-in-restore-trial-for-retinitis-pigmentosa 2024-04-02 0.50 https://www.ophthalmologytimes.com/view/outlook-therapeutics-receives-positive-chmp-opinion-for-bevacizumab-for-wet-age-related-macular-degeneration 2024-03-25 0.50 https://www.ophthalmologytimes.com/view/study-shows-minocycline-has-no-benefit-in-slowing-geographic-atrophy-expansion-in-patients-with-dry-age-related-macular-degeneration 2024-03-25 0.50 https://www.ophthalmologytimes.com/view/korean-study-shows-increased-risk-of-amd-among-air-force-pilots 2024-03-25 0.50 https://www.ophthalmologytimes.com/view/diagnosis-and-management-of-solar-retinopathy 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/unraveling-the-role-of-modifier-genes-in-retinitis-pigmentosa-type-59-a-study-on-alg6-variant-effects 2024-03-21 0.50 https://www.ophthalmologytimes.com/view/arxvision-integrates-with-microsoft-seeing-ai-app-and-navilens-app-to-enhance-accessibility-solutions-for-blind-low-vision-patients 2024-03-21 0.50 https://www.ophthalmologytimes.com/view/case-2-treatment-experienced-namd-switch-to-aflibercept-8mg 2024-03-22 0.50 https://www.ophthalmologytimes.com/view/clinical-perspectives-comparing-faricimab-and-aflibercept-8mg 2024-03-22 0.50 https://www.ophthalmologytimes.com/view/perspectives-on-loading-dose-and-treatment-extension-with-new-therapies 2024-03-22 0.50 https://www.ophthalmologytimes.com/view/tolerance-and-aggression-achieving-improved-fluid-response 2024-03-22 0.50 https://www.ophthalmologytimes.com/view/perspectives-on-retinal-fluid-management-in-namd-and-dme 2024-03-22 0.50 https://www.ophthalmologytimes.com/view/protecting-vision-during-the-2024-solar-eclipse 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/case-1-discussion-of-treatment-na-ve-namd-with-aflibercept-8mg 2024-03-22 0.50 https://www.ophthalmologytimes.com/view/ophthalmology-foundation-elects-new-board-members-and-officers 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/ocular-injuries-after-motor-vehicle-accidents-long-term-effects-on-quality-of-life 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/topical-drop-treatment-for-full-thickness-macular-hole-closure 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/projections-show-anticipated-rapid-expansion-of-retinal-vein-occlusion-market- 2024-03-19 0.50 https://www.ophthalmologytimes.com/view/clinical-trials-what-to-keep-in-mind 2024-03-14 0.50 https://www.ophthalmologytimes.com/view/advanced-retinoblastoma-characterized-by-low-expression-of-nr1d1-and-nr2e3 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/key-takeaways-from-the-davio-2-study-with-rishi-singh-md 2024-03-18 0.50 https://www.ophthalmologytimes.com/view/why-wait-the-data-show-administering-steroids-to-dme-patients-with-good-vision-leads-to-long-term-success 2024-03-14 0.50 https://www.ophthalmologytimes.com/view/iss-national-lab-sponsored-study-to-test-a-novel-gene-therapy-for-amd 2024-03-18 0.50 https://www.ophthalmologytimes.com/view/new-dawn-of-ga-management-requires-renewed-attention-to-imaging 2024-03-14 0.50 https://www.ophthalmologytimes.com/view/tease-3-study-positive-interim-data-reported-for-stargardt-drug 2024-03-14 0.50 https://www.ophthalmologytimes.com/view/cophy-2024-should-all-patients-with-idiopathic-intracranial-hypertension-have-a-lumbar-puncture- 2024-03-13 0.50 https://www.ophthalmologytimes.com/view/patients-with-visual-snow-syndrome-should-be-evaluated-and-treated 2024-03-12 0.50 https://www.ophthalmologytimes.com/view/send-elderly-patients-with-acute-visual-loss-to-er-for-stroke-evaluation-and-treatment-a-resounding-yes 2024-03-12 0.50 https://www.ophthalmologytimes.com/view/aligning-clinical-trial-retreatment-criteria-to-clinical-practice 2024-03-15 0.50 https://www.ophthalmologytimes.com/view/overview-of-the-newest-therapies-for-amd-and-dme-faricimab-and-aflibercept-8mg 2024-03-15 0.50 https://www.ophthalmologytimes.com/view/cases-of-severe-intraocular-inflammation-after-intravitreal-faricimab 2024-03-15 0.50 https://www.ophthalmologytimes.com/view/cophy-2024-is-artificial-intelligence-ready-to-replace-physicians- 2024-03-14 0.50 https://www.ophthalmologytimes.com/view/intraocular-inflammation-a-major-risk-factor-resulting-from-use-of-anti-complement-agents-for-ga 2024-03-22 0.50 https://www.ophthalmologytimes.com/view/protecting-vision-during-solar-eclipses-insights-for-ophthalmologists 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/humanity-technology-talking-to-patients-about-the-science-and-benefits-of-clinical-trials 2024-03-14 0.50 https://www.ophthalmologytimes.com/view/cophy-2024-how-good-are-we-really-without-artificial-intelligence-tools- 2024-03-14 0.50 https://www.ophthalmologytimes.com/view/ocugen-completes-dosing-of-subjects-with-geographic-atrophy-in-phase-1-2-clinical-trial-of-ocu410 2024-03-14 0.50 https://www.ophthalmologytimes.com/view/clario-and-cole-eye-institute-announce-strategic-partnership-to-provide-ophthalmology-offerings-for-clinical-trials 2024-03-14 0.50 https://www.ophthalmologytimes.com/view/ocuterra-announces-phase-2-dr-eam-trial-fails-to-meet-primary-and-secondary-key-endpoints 2024-03-14 0.50 https://www.ophthalmologytimes.com/view/seeing-a-new-reality 2024-03-19 0.50 https://www.ophthalmologytimes.com/view/smokers-more-likely-to-experience-vision-loss 2024-03-13 0.50 https://www.ophthalmologytimes.com/view/philip-ferrone-md-to-join-apellis-pharmaceuticals-as-chief-medical-retina-advisor 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/study-researchers-demonstrate-prime-editing-as-option-to-correct-many-disease-causing-genetic-mutation 2024-03-09 0.50 https://www.ophthalmologytimes.com/view/regeneron-announces-publication-of-one-year-results-from-pulsar-and-photon-trials 2024-03-09 0.50 https://www.ophthalmologytimes.com/view/kiora-publishes-results-from-study-demonstrating-safety-tolerability-and-efficacy-of-kio-101-for-treatment-of-inflammation-of-the-eye 2024-03-09 0.50 https://www.ophthalmologytimes.com/view/coherus-completes-divestiture-of-ophthalmology-franchise 2026-06-30 0.50 https://www.ophthalmologytimes.com/view/role-of-biosimilars-in-namd-and-dme-step-therapy 2024-03-08 0.50 https://www.ophthalmologytimes.com/view/navigating-step-therapy-in-namd-and-dme 2024-03-08 0.50 https://www.ophthalmologytimes.com/view/predicting-visual-acuity-from-patient-data-with-a-machine-learning-multistage-system 2024-03-07 0.50 https://www.ophthalmologytimes.com/view/risk-of-cancer-and-amd 2024-03-04 0.50 https://www.ophthalmologytimes.com/view/chatbot-accuracy-in-ophthalmology-a-work-in-progress 2024-03-04 0.50 https://www.ophthalmologytimes.com/view/reaching-consensus-on-geographic-atrophy-diagnosis-and-management 2024-03-04 0.50 https://www.ophthalmologytimes.com/view/cophy-2024-facing-down-the-controversies-in-ophthalmology 2024-03-04 0.50